Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07252479 · ClinicalTrials.gov registry record · Phase 1
Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations
A Phase 1 study of RAS Mutation and Solid Tumors (Phase 1), sponsored by Adlai Nortye Biopharma Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 91
- Enrollment target
- 2
- Study locations
NCT07252479 is a Phase 1 study of RAS Mutation and Solid Tumors (Phase 1) that is actively recruiting participants, run by Adlai Nortye Biopharma Co.. The registered enrollment target is 91 participants, below the 341-participant average among 4 other RAS Mutation trials with a reported enrollment target (73% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT07252479, a Phase 1 study of RAS Mutation and Solid Tumors (Phase 1), is actively recruiting participants, sponsored by Adlai Nortye Biopharma Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 91 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this clinical trial is to learn determine if AN9025 is safe and tolerable to treat solid cancer tumors with specific genetic mutations. It will help identify doses for use in future testing and establish the safety profile of the drug. The main questions it aims to answer are: Which dose(s) of AN9025 are safe and tolerable for use in evaluating anti-tumor activity in participants with Rat Sarcoma oncogene (RAS) mutated solid tumors? What medical problems do participants have when taking AN9025? Participants will: Take AN9025 by mouth every day until their disease progresses, they experience severe ill side effects from taking the drug, or withdraw from the study due to their own choice or as recommended by their physician. Visit the clinic 3-4 times during the first 21 days of treatment for study testing, blood draws and tumor tissue sample collection (if needed). The blood draws will be used to check drug levels in the participants blood for research purposes. Visit the clinic every 21 days for checkups and tests and monitoring of participant progress. Return to the clinic at 14 and 30 days after AN9025 treatment is stopped. Participants will be contacted every 3 months to check on the participants disease status and general well being. Participants may also partake in a food effect study, where the effect of eating is studied to see if there is any effect on AN9025 in the body.
Conditions Studied
Interventions
- DRUG AN9025 oral capsule
Study Locations (2)
Florida
- Sarah Cannon Research Institute at Florida Cancer Specialists - Orlando
Texas
- University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2026-01-28 |
| Est. Completion | 2028-06-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07252479
The ClinicalTrials.gov registry entry for NCT07252479 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 91 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 341-participant average among 4 other RAS Mutation trials with a reported enrollment target (73% lower). The listed sponsor is Adlai Nortye Biopharma Co., which has 6 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with RAS Mutation appearing as the primary indexed condition, and to 1 intervention - of which AN9025 oral capsule is the first listed.
NCT07252479 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT07252479 about?
NCT07252479 is a clinical study titled "Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations". The goal of this clinical trial is to learn determine if AN9025 is safe and tolerable to treat solid cancer tumors with specific genetic mutations. It will help identify doses for use in future testing and establish the safety profile of the drug. The main questions it aims to answer are: Which dos...
What is the current status of trial NCT07252479?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 91 participants. The study started on 2026-01-28. Estimated completion is 2028-06-01.
What conditions does trial NCT07252479 study?
This clinical trial studies the following conditions: RAS Mutation, Solid Tumors (Phase 1).
What interventions are being tested in trial NCT07252479?
The interventions under investigation include: AN9025 oral capsule (DRUG).
Who is sponsoring clinical trial NCT07252479?
This trial is sponsored by Adlai Nortye Biopharma Co., which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07252479 being conducted?
This trial has 2 study locations across Florida, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for RAS Mutation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
RECRUITING · Phase 1
-
PAS-004 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
RECRUITING · Phase 1
-
RASopathy Biorepository
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.